Sanofi

Sanofi has cut 229 jobs tied to the Blueprint Medicines operation in Cambridge and closed the old headquarters it retained after acquiring the company a year earlier. The reductions affect staff associated with the Cambridge Blueprint unit as Sanofi consolidates operations following the buyout. The article cites the specific headcount of 229 positions eliminated and notes the closure of the former Blueprint HQ building. Sanofi presented the cuts as part of post-acquisition restructuring and consolidation of facilities in the Boston-area campus. Local impacts include loss of jobs in Cambridge and the shuttering of the older office site within a year of the acquisition.

Sanofi will lay off 229 employees from acquired Blueprint Medicines in Massachusetts as part of a post-acquisition integration program about a year after completing the $9.1 billion takeover. The reductions, disclosed in a Massachusetts WARN filing, are scheduled to occur between October 2026 and June 2027 and will coincide with the closure of two former Blueprint sites in Cambridge and consolidation to Sanofi’s Cambridge Crossing campus. Blueprint reported 682 full-time employees before the acquisition, and Sanofi says the cuts affect roughly one-third of that pre-acquisition workforce; the company framed the move as aligning operations with long-term priorities and offering support for affected workers. The restructuring comes under new CEO Belén Garijo and reflects common post-acquisition consolidation to remove duplicative functions and reduce costs.